Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2020

View Archived Issues

MMA induces epithelial-to-mesenchymal transition

CAR T cells for inhibition

First healthy volunteers enrolled in phase I study of GRAd-COV2 COVID-19 vaccine candidate

Trevena initiates proof-of-concept study of TRV-027 in patients with COVID-19

BIIB-091: a potent, highly selective BTK inhibitor for the treatment of multiple sclerosis

GB-1211, first orally available galectin-3 inhibitor as potential treatment for NASH

Nicotinamide riboside suppresses inflammatory activation of PBMC in heart failure

Kyorin Pharmaceutical presents new 15-PGDH inhibitors

New DNA polymerase theta inhibitors discovered at Ideaya Biosciences

Foghorn Therapeutics patents PROTACs targeting BRD9

Canwell Biotech identifies new TLR7/8 agonists

New sphingomyelin phosphodiesterase 3 inhibitors discovered at Johns Hopkins University

Antifungal immunity helps out antibacterial vaccine

FDA clears IND for phase II study of RGX-314 for diabetic retinopathy

Immunogenicity of an saRNA lipid NP vaccine candidate encoding the SARS-CoV-2 S protein in mice

Topline data presented from phase II ELEKTRA study of soticlestat

AtlasMedx initiates phase I/II study of AMXI-5001 in advanced malignancies

Positive topline data from phase IIa trial of IMVT-1401 in myasthenia gravis

Mereo BioPharma initiates phase Ib/II study of alvelestat in COVID-19 respiratory disease

Phase III ASCEMBL study of asciminib in CML meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...